Insulin Analogues: The CADTH Experience · insulin analogues by transferring optimal therapy knowledge to policy makers, health care professionals and consumers. Ongoing and Re-assessment

• Horizon Scanning

• Early Assessment

• HTIS

Innovation and R&D

Adoption Decisions

Ongoing and Re-assessment

Obsolescence Decisions

• HTA

• HTIS

• CDR (Drugs)

• HTA

• HTIS

• CDR

• COMPUS

• HTA

• HTIS

Insulin Analogues: The CADTH Experience

Optimal Utilisation

• HTA

• COMPUS

Emerging Drug List

� Insulin detemir

for diabetes

mellitus (Jul 04)

� Insulin aspart

(Feb 02)

� Insulin glargine

(May 01)

Issues in Emerging Technologies

• Insulin Glargine for Type 2 Diabetes (Aug 2004)

• Insulin glargine: a long-acting insulin for Diabetes Mellitus (Nov 2003)

• Inhaled Insulin for the Treatment of Diabetes Mellitus (June 2001)

Liaison Program and Knowledge Transfer



• HTIS

Innovation and R&D



• HTA

• HTIS

• CDR (Drugs)

• HTA

• HTIS

Optimal Utilisation

• HTA

• COMPUS


Health Technology Reports• Long-acting Insulin Analogues for Diabetes Mellitus: Meta-analysis of

Clinical Outcomes and Assessment of Cost-Effectiveness (Oct 2007)

• Short-acting insulin analogues for Diabetes Mellitus: Meta-analysis of

Clinical Outcomes and Assessment of Cost-Effectiveness (Mar 2007)

• Insulin Lispro: A Critical Evaluation (Feb 1999)


Technology Overviews• Insulin Analogues for Diabetes

Mellitus: Review of Clinical

Efficacy and Cost-Effectiveness

(Oct 2007)

Adoption Decisions

CDR Reviews and Recommendations

Insulin glulisine (Apidra)• Submission status report

Insulin detemir (Levemir)• Submission status report

• Recommendation and reasons

Insulin aspart/insulin aspart protamine (NovoMix 30)• Submission status report


Insulin glargine (Lantus) (Initial submission)• Submission Status Report


• HTA

• HTIS

• CDR

• COMPUS



• HTIS

Innovation and R&D


• HTA

• HTIS

• CDR (Drugs)

• HTA

• HTIS

• HTA

• COMPUS


Health Technology Reports• Long-acting Insulin Analogues for Diabetes

Mellitus: Meta-analysis of Clinical Outcomes and

Assessment of Cost-Effectiveness (Oct 2007)

• Short-acting insulin analogues for Diabetes


Assessment of Cost-Effectiveness (Mar 2007)






(Oct 2007)

Adoption Decisions

• HTA

• HTIS

• CDR

• COMPUS

Optimal Therapy Reports• Draft Gap Analysis and Key Messages for the Prescribing and Use of

Insulin Analogues (Sept 2008)

• Draft Optimal Therapy Recommendations for the Prescribing and Use

of Insulin Analogues (June 2008)

• Long-acting Insulin Analogues: Meta-analyses of Clinical Outcomes

(Update of CADTH Technology Report No. 92) (Mar 2008)

• Current Utilization of Insulin Products in Canada (Mar 2008)

• An Economic Evaluation of Insulin Analogues (Mar 2008)

• Rapid-acting Insulin Analogues: Meta-analyses of Clinical Outcomes

(Update of CADTH Technology Report No. 87)

• Current Practice Analysis: A Qualitative Analysis of Canadian

Physician Perceptions and Use of Insulin Analogues (Jan 2008)

• GRADE Evidence Profiles on Long-acting and Rapid-acting Insulin

Analogues (Jan 2008)

CDR Reassessments

Insulin glargine (Lantus) (Resubmission)Submission Status Report

Recommendation and reasons

Optimal Utilisation




• HTIS

Innovation and R&D


• HTA

• HTIS

• CDR (Drugs)

• HTA

• HTIS

• HTA

• COMPUS













(Oct 2007)

Adoption Decisions

• HTA

• HTIS

• CDR

• COMPUS

Optimal Therapy Reports• Draft Gap Analysis and Key Messages for the Prescribing and Use of

Insulin Analogues (Sept 2008)

• Draft Optimal Therapy Recommendations for the Prescribing and Use

of Insulin Analogues (June 2008)

• Long-acting Insulin Analogues: Meta-analyses of Clinical Outcomes

(Update of CADTH Technology Report No. 92) (Mar 2008)

• Current Utilization of Insulin Products in Canada (Mar 2008)

• An Economic Evaluation of Insulin Analogues (Mar 2008)

• Rapid-acting Insulin Analogues: Meta-analyses of Clinical Outcomes

(Update of CADTH Technology Report No. 87)

• Current Practice Analysis: A Qualitative Analysis of Canadian

Physician Perceptions and Use of Insulin Analogues (Jan 2008)

• GRADE Evidence Profiles on Long-acting and Rapid-acting Insulin

Analogues (Jan 2008)

Optimal Utilisation

Intervention Tools

•A suite of intervention tools will be available in 2009. These

tools will be designed to influence the prescribing and use of

insulin analogues by transferring optimal therapy knowledge to

policy makers, health care professionals and consumers.




• HTIS

Innovation and R&D


• HTA

• HTIS

• CDR (Drugs)

• HTA

• HTIS

• HTA

• COMPUS












(Oct 2007)

Adoption Decisions

• HTA

• HTIS

• CDR

• COMPUS

Optimal Utilisation



Documents

Insulin Analogues: The CADTH Experience · insulin analogues by transferring optimal therapy knowledge to policy makers, health care professionals and consumers. Ongoing and Re-assessment